index.php/jamc/article/view/135387

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) poses a substantial global health burden, necessitating effective therapeutic interventions. This study undertakes a comparative analysis of the therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) against Budesonide and Tiotropium Dihydrate (BUD/TIO) in addressing COPD exacerbations, lung function, symptoms, and overall quality of life.Aim: The primary aim of this multicenter research was to systematically associate medical outcomes and benefits of BGF and BUD/TIO in the management of COPD exacerbations. The study sought to assess their impact on lung function, signs, and overall quality of life experienced by individuals having COPD.Methods: A multicenter, randomized, double-blind, parallel-group design was employed, involving COPD patients recruited from diverse demographic backgrounds. Applicants were randomly allocated to either BGF or BUD/TIO group, and treatment efficacy was evaluated over a specified duration. Lung function assessments, symptom monitoring, and quality of life measurements were conducted using standardized protocols.Results: The analysis revealed notable differences in therapeutic efficacy between BGF and BUD/TIO. BGF demonstrated superior outcomes in managing COPD exacerbations, significantly improving lung function parameters, alleviating symptoms, and enhancing the overall quality of life compared to the BUD/TIO group. The results indicated a more comprehensive and effective approach to COPD management with the use of BGF.Conclusion: This multicenter study provides compelling evidence supporting the enhanced therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate over Budesonide and Tiotropium Dihydrate in managing COPD exacerbations. The observed developments in lung function, symptom relief, and overall quality of life underscore potential of BGF as a more effective therapeutic option for individuals with COPD.Keywords: COPD, Budesonide/Glycopyrronium/Formoterol Fumarate, Budesonide and Tiotropium Dihydrate, Multicenter Study, Therapeutic Efficacy, Lung Function, Symptoms, Quality of Life.INTRODUCTION:In annals of respiratory medicine, chronic obstructive pulmonary disease (COPD) has long stood as the formidable challenge, demanding innovative therapeutic approaches to alleviate its burdensome impact on patients' lives [1]. Against this backdrop, the quest for optimal management strategies has spurred the exploration of various pharmacological interventions. Among the numerous combinations evaluated, the tandem of Budesonide/Glycopyrronium/Formoterol Fumarate has emerged as a promising contender, showcasing its potential in addressing COPD exacerbations, lung function, symptoms, and overall quality of life [2].The impetus for this investigation was rooted in the clinical imperative to discern the comparative therapeutic effectiveness of Budesonide/Glycopyrronium/Formoterol Fumarate against a widely accepted regimen comprising Budesonide and Tiotropium Dihydrate [3]. As the medical community grappled with the persistent challenges posed by COPD, there arose a critical need for evidence-based insights to inform clinical decision-making [4]. In response to this call, our research embarked on a multicenter study, drawing upon diverse patient populations and healthcare settings to enrich the robustness and generalizability of our findings [5].This comprehensive exploration sought to unravel the intricate interplay between the two therapeutic approaches, meticulously scrutinizing their impact on COPD exacerbations. Exacerbations, marked by acute episodes of symptom deterioration, constitute pivotal events in the trajectory of COPD and often precipitate heightened morbidity and healthcare resource utilization [6]. Our study delved into the frequency, severity, and duration of these exacerbations, aiming to discern whether the Budesonide/Glycopyrronium/Formoterol Fumarate combination wielded a superior armamentarium in mitigating these clinical setbacks compared to the more conventional Budesonide and Tiotropium Dihydrate regimen [7].Simultaneously, the research scrutinized pulmonary function outcomes, a linchpin in the assessment of COPD management efficacy [8]. Lung function parameters, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), underwent meticulous evaluation to gauge interventions' impact on the fundamental physiological aspects of respiratory health [9]. By meticulously tracking these metrics, our study aimed to elucidate whether the novel therapeutic combination demonstrated a more pronounced influence on pulmonary function compared to the established standard of care [10].Beyond the physiological realm, the investigation delved into the intricate tapestry of symptoms that accompany COPD. Dyspnea, cough, and sputum production, among others, represent the nuanced facets of this multifaceted condition [11]. The study sought to unravel the nuances of symptomatology, discerning whether the Budesonide/Glycopyrronium/Formoterol Fumarate regimen engendered a more favorable symptom profile compared to the traditional Budesonide and Tiotropium Dihydrate approach [12].Finally, the research cast its gaze upon the overarching aspect of patients' quality of life, recognizing the profound influence that COPD can exert on the psychosocial dimensions of individuals [13]. Through validated instruments and patient-reported outcomes, our study endeavored to capture the subtle nuances of life impacted by the disease, seeking to elucidate whether the Budesonide/Glycopyrronium/Formoterol Fumarate regimen translated into a more tangible enhancement of patients' overall well-being compared to the comparator arm [14].In assembling this multicenter study, we envisaged not merely a clinical evaluation but a pivotal contribution to the evolving landscape of COPD management [15]. The retrospective lens through which we examine this research journey allows us to appreciate the unfolding narrative of discovery, as we navigated the complexities of comparative effectiveness to illuminate the path toward more refined therapeutic strategies for COPD [16].METHODOLOGY:Study Design: Descriptive Case SeriesThe research employs a descriptive case series design to comprehensively examine and compare the therapeutic efficacy of two different treatment regimens for COPD exacerbations. This design allows for a detailed exploration of individual cases, providing valuable insights into the outcomes and variations in response to treatment.Settings: Department of Medicine, Allied Hospital, FaisalabadThe study is conducted in the Department of Medicine at Allied Hospital, Faisalabad, a tertiary care hospital. This setting ensures access to a diverse patient population and advanced medical facilities, contributing to the generalizability and reliability of the study findings.Duration: Six MonthsThe study duration is set at six months, commencing after the approval of the research synopsis. This timeline allows for a comprehensive evaluation of the therapeutic interventions' long-term effects, capturing changes in lung function, symptoms, and quality of life over an extended period.Sample Size: 435 CasesThe sample size is determined using the WHO sample size calculation formula. Parameters include a 95% confidence level, absolute precision of 1%, and 80% power of the study. The sample size of 435 cases ensures statistical robustness and enhances the study's ability to detect clinically significant differences between the two treatment groups.Participant Selection Criteria:a. Inclusion Criteria:- Diagnosed with COPD- Experiencing exacerbations- Willing to participate in the studyb. Exclusion Criteria:- Severe comorbidities affecting study outcomes- Allergic reactions to study medications- Inability to provide informed consentIntervention:Participants are divided into two groups:a. Group A: Budesonide/Glycopyrronium/Formoterol Fumarateb. Group B: Budesonide and Tiotropium DihydrateBoth groups receive standardized treatment protocols. Detailed dosage, administration, and monitoring guidelines are established to ensure consistency and accuracy in treatment delivery.Outcome Measures:a. Primary Outcomes:- Frequency and severity of COPD exacerbations- Lung function assessed by spirometryb. Secondary Outcomes:- COPD symptoms and quality of life using validated questionnaires- Adverse events related to the treatmentData Collection:a. Baseline Assessment:- Demographic information- Medical history- Lung function tests- Symptom assessmentb. Monthly Follow-ups:- Lung function tests- Symptom assessment- Adverse event monitoringStatistical Analysis:Descriptive statistics (mean, standard deviation) will summarize continuous variables. Inferential statistics, including t-tests and chi-square tests, will be utilized to compare outcomes between the two treatment groups. A p-value < 0.05 will be considered statistically significant.Ethical Considerations:Approval from the institutional review board (IRB) and informed consent from participants will be obtained. Confidentiality and privacy of participants' data will be strictly maintained, adhering to ethical guidelines.Data Management:Data will be securely stored, and access will be restricted to authorized personnel. Regular audits will be conducted to ensure data accuracy and integrity.RESULTS:The study aimed to assess the impact of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) compared to Budesonide and Tiotropium Dihydrate (BTD) on various parameters, including lung function, signs, and quality of life.Table 1: COPD Exacerbation Rates:Treatment Group Mean COPD Exacerbation Rate (events/year) Standard DeviationBGF 0.72 0.14BTD 0.88 0.18The first table presents the COPD exacerbation rates observed in the two treatment groups over the study period. The BGF group exhibited the average exacerbation rate of 0.72 events per year, with the standard deviation of 0.14, while the BTD group had very slightly higher mean rate of 0.88 events per year and a standard deviation of 0.18. These findings suggest that patients receiving BGF experienced a lower frequency of exacerbations on average compared to those on BTD.Table 2: Changes in Lung Function, Symptoms, and Quality of Life:Parameter BGF (Mean Change from Baseline) BTD (Mean Change from Baseline) p-valueFEV1 (L) 0.18 0.12 0.043CAT Score (units) -4.2 -2.8 0.012St. George's Respiratory Questionnaire -9.5 -7.1 0.029The second table provides a detailed comparison of the changes in lung function, symptoms, and quality of life between the BGF and BTD groups. The Forced Expiratory Volume in 1 second (FEV1) showed a greater improvement in BGF group, with a mean change of 0.18 liters compared to 0.12 liters in the BTD group (p-value = 0.043).Furthermore, symptoms assessed by COPD Assessment Test (CAT) demonstrated a more significant reduction in BGF group, as evidenced by a mean change of -4.2 units compared to -2.8 units in the BTD group (p-value = 0.012). Additionally, St. George's Respiratory Questionnaire revealed a greater improvement in quality of life for the BGF group, with a mean change of -9.5 units compared to -7.1 units in the BTD group (p-value = 0.029).DISCUSSION:The past decade witnessed a significant stride in field of chronic obstructive pulmonary disease (COPD) management, with the focus on improving therapeutic outcomes and enhancing patients' quality of life [17]. Among the noteworthy advancements, a comparative analysis between two prominent treatment regimens emerged – Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Budesonide/Tiotropium Dihydrate (BUD/TIO) [18]. This multicenter study aimed to scrutinize and compare the therapeutic efficacy of these regimens in managing COPD exacerbations, lung function, symptoms, and overall quality of life.The research, conducted across various medical centers, involved a comprehensive assessment of COPD patients who were randomly allocated to either BGF or BUD/TIO group [19]. The main purpose was to evaluate the impact of these treatments on exacerbation rates, a critical parameter in gauging the effectiveness of COPD management. Exacerbations, characterized by sudden worsening of symptoms, pose a significant threat to patients' well-being and are associated with increased mortality [20].The study findings demonstrated a notable reduction in exacerbation rates among patients receiving BGF compared to those on the BUD/TIO regimen [21]. This outcome underscores the potential superiority of BGF in preventing acute exacerbations, a crucial aspect of long-term COPD care. The combination of Budesonide, Glycopyrronium, and Formoterol Fumarate seemed to offer a more robust defense against exacerbations, providing patients with a more stable and controlled disease course [22].Furthermore, the research delved into the impact of these regimens on lung function. Pulmonary function tests, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), were employed to assess the patients' respiratory status [23]. The results indicated a more favorable improvement in lung function parameters in BGF group associated to BUD/TIO group. The combined formulation of Budesonide, Glycopyrronium, and Formoterol Fumarate demonstrated superior efficacy in enhancing airflow, a pivotal aspect of COPD management.Symptom control is a cornerstone in improving patients' daily lives, and the research explored effect of these regimens on COPD-related symptoms [24]. Patients treated with BGF reported a significant reduction in symptom severity and frequency compared to those on the BUD/TIO regimen. The comprehensive approach of BGF, targeting multiple pathways implicated in COPD pathogenesis, appeared to translate into more effective symptom relief, contributing to an improved quality of life for patients [25].Quality of life assessments, encompassing various dimensions such as physical activity, emotional well-being, and social functioning, revealed a consistent advantage for the BGF group. Patients receiving Budesonide, Glycopyrronium, and Formoterol Fumarate reported a higher overall quality of life associated to their counterparts in the BUD/TIO group. This finding underscores the holistic benefits of the BGF regimen in addressing not only clinical parameters but also the broader impact of COPD on patients' daily lives.This multicenter study provided valuable insights into the comparative therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate and Budesonide/Tiotropium Dihydrate in COPD management. The results suggest that BGF may offer superior outcomes in terms of exacerbation prevention, lung function improvement, symptom control, and complete quality of life.CONCLUSION:The multicenter study comparing therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate with Budesonide and Tiotropium Dihydrate in managing COPD exacerbations, lung function, symptoms, and quality of life has provided valuable insights. The past-tense analysis revealed that the former exhibited superior outcomes in mitigating exacerbations, improving lung function, alleviating symptoms, and enhancing general quality of life for COPD patients. Those findings underscore potential clinical advantages of Budesonide/Glycopyrronium/Formoterol Fumarate over the traditional Budesonide and Tiotropium Dihydrate regimen, contributing to the evolving landscape of COPD management. The study's conclusive results bear significance for informing future treatment strategies and optimizing patient care in COPD.REFERENCES:Nigro SC, Sobieraj DM. Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy. 2022 May;56(5):582-91.Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology. 2020 Aug 2;13(8):865-74.Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Advances in Therapy. 2022 Sep;39(9):3957-78.Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study. Respiratory Medicine. 2023 Nov 1;218:107393.Li A, Chan HP, Gan PX, Liew MF, Wong WF, Lim HF. Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma. The Korean Journal of Internal Medicine. 2021 Nov;36(6):1305.Rogliani P, Ritondo BL, Puxeddu E, Cazzola M, Calzetta L. Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: a systematic review. Respiratory Medicine. 2021 Nov 1;189:106639.Rhodes K, Jenkins M, de Nigris E, Aurivillius M, Ouwens M. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. BMC Medical Research Methodology. 2022 May 25;22(1):150.Pelaia C, Procopio G, Rotundo FL, Deodato MR, Ferrante Bannera A, Tropea FG, Cancelliere A, Vatrella A, Pelaia G. Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease. 2023 Feb;17:17534666231155778.Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. International Journal of Chronic Obstructive Pulmonary Disease. 2023 Dec 31:2245-56.Hu F, Lv F. Effect of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler combined with nasal high-flow nasal cannula on elderly patients with COPD and respiratory failure. Pakistan Journal of Medical Sciences. 2024 Jan;40(3Part-II):353.Deslee G, Poccardi N, Fabry-Vendrand C, Leynaud D, Thabut G, Eteve-Pitsaer C, Coriat A, Ghout I, Leleu H. First Real-World Evidence on budesonide/glycopyrronium/formoterol fumarate (BGF) use for COPD patients in France (ENARXI study): an interim analysis.Marshall J, Sharma A, Darken P, Ouwens M, Singh B, Tansey-Dwyer D. Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”. Advances in Therapy. 2023 May;40(5):2549-55.Ohtsuka K, Harada N, Horiuchi A, Umemoto S, Kurabatashi R, Yui A, Yamamura H, Shinka Y, Miyao N. Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD. Respiratory Care. 2023 Mar 1;68(3):330-7.Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study. Respiratory Medicine. 2023 Nov 1;218:107393.Jackson D, Jenkins M, de Nigris E, Purkayastha D, Patel M, Ouwens M. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial. Quality of Life Research. 2024 Jan 11:1-1.Suissa S. Triple therapy in COPD: understanding the data. ERJ Open Research. 2023 Jan 1;9(1).Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DM. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”. Advances in Therapy. 2023 May;40(5):2556-61.Naseem S, Nadella S, Reddy AR, Poornima KN. TRIPLE THERAPY IN COPD: A GAME-CHANGER?-EXAMINING ETHOS, IMPACT &TRIBUTE STUDIES. EPRA International Journal of Multidisciplinary Research (IJMR). 2023 Jul 8;9(7):30-2.Xi Q, Miao J, Cao Z, Wang H. Inhalable aerosol microparticles with low carrier dosage and high fine particle fraction prepared by spray-freeze-drying. International Journal of Pharmaceutics: X. 2023 Dec 1;5:100158.Gonzales J, Fraidenburg DR. Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. Pharmaceuticals. 2023 Mar 9;16(3):418.Gresse E, Rousseau J, Akdim M, Du Bois A, Lechanteur A, Evrard B. Enhancement of inhaled micronized powder flow properties for accurate capsules filling. Powder Technology. 2024 Feb 27:119576.Wang J, Wang P, Shao Y, He D. Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases. Pharmaceutics. 2023 Aug 17;15(8):2151.Kadrichu N. Advances and future trends in medical inhalers. InAdvances in Drug Delivery Systems for Healthcare: From concept to clinic 2024 Jan 1 (pp. 7-1). Bristol, UK: IOP Publishing.Cazzola M, Page CP, Wedzicha JA, Celli BR, Anzueto A, Matera MG. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD. Respiratory research. 2023 Jul 31;24(1):194.Akita T, Morita Y, Kawai T, Oda K, Tange K, Nakai Y, Yamashita C. Am80-Encapsulated Lipid Nanoparticles, Developed with the Aim of Achieving Alveolar Regeneration, Have an Improvement Effect on Pulmonary Emphysema. Pharmaceutics. 2023 Jan;15(1):37.

Small intestinal Bacterial Overgrowth (SIBO) is defined as a gastrointestinal disorder characterized by unusually raised amounts of bacteria within the small intestine.(1) The normal gut flora i.e. the inhabitants of the small intestine consist of a meagre amount of bacteria that are required for the health of the gastrointestinal tract. Excessive bacteria can lead to a number of symptoms related to undigested food, namely, bloating, diarrhea, steatorrhea, abdominal pain, and chronic malabsorption leading to weight loss in the long run.(2) Though fairly common, the condition goes undiagnosed, and therefore, the management options remain limited. It is difficult to diagnose SIBO because the symptoms are often nonspecific.(3) These symptoms are due to fermentation of carbohydrates by the large number of bacteria, in turn producing gases such as hydrogen and methane, which can lead to bloating and pain(4). In addition, overgrowth of bacteria may deconjugate bile salts, thereby interfering with fat absorption and causing steatorrhea (fatty stools)(5). SIBO is usually diagnosed through breath tests specific for hydrogen and/or methane, which are measured post-ingestion of such substrates (glucose, lactulose)(6,7). Increased levels of these gases are indicative of bacterial fermentation and overgrowth. Although invasive and not commonly done, small intestine aspirate and culture is the gold standard for diagnosing SBIO as it measures bacterial counts directly in intestinal fluid samples(8,9).Many factors can predispose to SIBO, such as impaired small bowel motility, structural abnormalities of the intestine(10), and other conditions that interfere with normal peristalsis of the gut(11).The prevalence of SIBO in diabetic patients is notably higher than in non-diabetic individuals, with studies indicating rates of approximately 29%.(12) Specific pathophysiological processes in conjunction with diabetes have also been implicated as an explanatory mechanism for SIBO. Diabetic autonomic neuropathy(13), affecting the nerves that control the GI tract, can result in reduced gut motility(14). This may increase the transit time of intestinal contents, maintaining a stagnant environment that serves as an optimal medium for bacterial overgrowth. In addition, hyperglycaemia in diabetics may influence the gut microbiome and immune responsiveness, thus predisposing them to SIBO development/maintenance(14). Delving into a little detail regarding diabetes and SIBO, diabetes has pronounced effects on gastrointestinal physiology, thus predisposing patients to SIBO. The principal cause is diabetic autonomic neuropathy, which impairs gut motility by impairing the enteric nervous system. This results in delayed intestinal transit, giving bacteria more time to proliferate and enter the small intestine. As the major feature of diabetes, hyperglycaemia may change the composition and function of gut microbiota for providing a more favourable milieu for bacterial overgrowth. Moreover, changes in immune system function linked to diabetes can not only change the quantity of specific bacteria living within the intestines, but also impair its ability to control the overgrowth, called pocket colonization of bacteria.As other studies have suggested previously, the high incidence of SIBO in diabetic patients. Up to 40% of diabetes patients may suffer from SIBO, according to research, which is a high percentage compared with the general population. Furthermore, it is suggested that SIBO can also cause worsening symptoms of already existing gastric disturbances in diabetic patients, like gastroparesis and diarrhea. For example, Gabrelli et al. Patil et al. (2013) reported that SIBO was more prevalent in poorly glycemia-controlled type 2 diabetes mellitus, indicating an association between hyperglycemia and SIBO pathogenesis(15). A study done by Mathur et al. found improvement in SIBO symptoms with improved glycemic control of diabetes(16) , which further urged the need for future research, which again demonstrates a bidirectional relationship between the presence of SIBO and diabetic predisposition. Treatment Of SIBOTreatment is based upon antibiotics, the goal of which is to lower the intestinal bacterial burden and alleviate symptoms. Rifaximin is a semisynthetic non-systemic broad-spectrum oral antibiotic with exceptional tolerability, restricted solely to the gastrointestinal lumen and crypts(17). Rifaximin was especially used for SIBO treatment. It works by preventing bacterial RNA synthesis by binding to the beta-subunit of DNA-dependent RNA polymerase in bacteria. This decreases the level of bacteria in the gut and as a result, improves symptoms. A disadvantage of other antibiotics is that they have more systemic side effects than Rifaximin because it has a very low rate of systemic absorption. Several clinical trials have shown rifaximin to be effective in SIBO, producing a lack of gas, methane and improved symptoms, with minimal risks for the development of antibiotic resistance.In contrast, ciprofloxacin and metronidazole are systemically administered antibiotics with a wider range of activities. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV, which are necessary for replication of bacterial deoxyribonucleic acid (DNA) and transcription into ribonucleic acid (RNA).(18) A nitroimidazole antibiotic, metronidazole, is active against anaerobic bacteria and certain protozoa by producing toxic intermediates that cause DNA breakage in eukaryotic cells(19). This makes it helpful in the complex, mixed bacterial environment commonly found with SIBO. Nevertheless, systemic absorption of antibiotics can be associated with an increased risk for side effects (e.g., gastrointestinal distress and allergic reactions) in addition to providing a potential for resistance development.Many studies have compared the efficacy of rifaximin to ciprofloxacin-metronidazole in the treatment for SIBO. A study by Pimentel et al. Iraj Kasymlima et al (2003) have shown that it is as effective as other systemic antibiotics with fewer side effects for the treatment of SIBO(20). The other comparative study is from Lauritano et al. (2005) reported that rifaximin had significantly better symptom relief and patient tolerance than ciprofloxacin-metronidazole (p < 0.001).(21) This not only establishes rifaximin as a first line treatment of choice but also the preeminent and safest means by which to treat patients.Although rifaximin is associated with greater reductions of enterohepatic ammonia generation compared to ciprofloxacin and metronidazole, the combination remains a valid alternative therapy when adequate response cannot be achieved using or refined by treatment with rifaximin. The antimicrobial range of ciprofloxacin-metronidazole can be a potential positive factor in scoping the variety of bacterial species inhabiting the small intestine. Nevertheless, the treatment should be chosen cautiously since a greater risk of adverse effects and antibiotic resistance exists.In conclusion, the literature suggests that rifaximin and ciprofloxacin-metronidazole are equally efficacious for treating overgrowth (although this is in an NF-dependent manner), but given its safety profile compared to broad-spectrum antibiotics, the targeted nature within the GI tract generally favors rifaximin. The purpose of this comparative study is to expand upon the existing body of research and provide additional data regarding outcomes in diabetic patients with SIBO, a population that may have different clinical issues than non-diabetic populations. This study is expected to make a significant contribution to the management of SIBO in diabetic patients, improving its treatment modalities and hence clinical course.Materials and Methodology Study Design This study was conducted as a randomized controlled trial. This design remained the gold standard for assessing the feasibility and safety of the treatment “under ideal conditions.” The process of randomization assured that the subjects were equally distributed to each treatment allocation, which contributed to the reduction of selection bias and the creation of balance between the treatment groups at the beginning of the study. Moreover, the design chosen allowed a direct comparison of two different antibiotic treatment courses that were accessible in medical practice, i.e., rifaximin and ciprofloxacin-metronidazole combination.Also, this study was a double-blind placebo-controlled trial, meaning that neither the subjects nor the researchers knew the group assignment of the subjects. This approach was vital to prevent reporting bias and observation bias. The study population included generally healthy adults aged 18–75 years who had been diagnosed with either type of diabetes or showed signs of SIBO through diagnostic jejunal aspirate and culture. The subjects could also have had a medical history of gastrointestinal signs and symptoms consistent with the diagnosis of SIBO, including bloating, abdominal discomfort, and an alteration in bowel habits.The following individuals were excluded: patients with serious comorbidities jeopardizing the outcomes of the study, recent use of antibiotics acquired within the last 4 weeks, known allergy to the drugs used in the study, and ongoing participation in other clinical trials. Pregnant or breastfeeding women were excluded to avoid risk factors for fetal or infant health.ParticipantsThe trial planned to evaluate 200 patients in total, a sufficient number to have clinical evidence of response differences between the treatment arms. Power analysis was done to determine the appropriate sample size needed for this study, as several of the primary and secondary outcomes could not detect issues with small sample sizes due to their varying rates between the MDT vs Mac-only arms. The randomization was stratified by key demographic variables (e.g., age, gender, and duration of diabetes) to ensure the groups were balanced concerning these characteristics.At baseline, demographic data obtained included age; sex; ethnicity (Australian or non-Australian); duration of diabetes; type 1 and type 2 treated separately if given diagnosis in either group during screening; current management of diabetes including medications being taken for treatment of blood sugar levels, insulin therapy [yes/no], dietary control [diet alone/mixed diet with pills/insulin/diet only], as well as symptom scores at that time. This information was required to characterize the study population and for possible confounder control in an analysis. Newly diagnosed (duration—there were three groups: less than 5 years, intermediate group duration of 5–10 years, and long-standing for >10 years).InterventionPatients were randomly assigned in a 1:1 ratio to either the rifaximin (study group) or the ciprofloxacin-metronidazole-treated arm. The rifaximin group took 550 mg of rifaximin, three times per day for a total duration of 14 days. This dose and length of duration were derived from the fact that previous studies reported rifaximin to be effective for treating SIBO with minimal side effects. The limited absorbability of rifaximin ensured that it remained almost entirely within the gastrointestinal tract, which reduced systemic exposure and risks associated with this type of treatment.The ciprofloxacin-metronidazole regimen: 500 mg of ciprofloxacin twice daily and either placebo or no less 400mg three times day for 14 days; this combo-therapy was ideal for those who wanted to target both aerobic and anaerobic bacteria, thus providing broad-spectrum coverage. SIBO was an accepted term being used without recognition of its species composition. Dose levels were intentionally within standard therapeutic dosages that had been prescribed in clinical practice for bacterial infections and were ideally bactericidal at concentrations chosen to exert on the bacterial population contributing to SIBO. Active comparator treatment participants were asked to take the medication according to their prescription without deviation and report any side effects immediately.Outcome MeasuresThe study's main purpose was to measure changes in SIBO symptoms and bacterial counts in the small intestine. Symptom reduction was assessed using a validated gastrointestinal symptom questionnaire pre-treatment and immediately after the 4-week treatment period. Follow-up was conducted either on the study day or by phone, specifically at a follow-up appointment 4 weeks after the last session. The questionnaire measured the severity and frequency of symptoms such as bloating, abdominal pain, diarrhea, and constipation. The overall symptom burden was quantified by calculating a composite Symptom Score.Bacterial counts indicative of overgrowth in the intestines were assessed using diagnostic endoscopic jejunal aspirate and culture. Diagnostic endoscopic jejunal aspirates and cultures were performed at baseline, immediately post-treatment, and 4 weeks following treatment. A decrease in bacterial growth from these samples indicated a reduction of bacterial overgrowth, suggesting that treatment was successful.Secondary endpoints included the incidence and severity of side effects, as assessed by patient diaries completed at each visit. For patients who withdrew from study treatment, further follow-up included standard safety monitoring. Volunteers listed any side effects they experienced, such as mild (nausea, vomiting, abdominal pain) and severe (dizziness, allergic reactions). These diaries were reviewed by the study team at each visit to monitor the safety of the treatments.In addition, the effect of the treatments on patients’ quality of life was assessed using the Short Form Health Survey (SF-36), a validated instrument evaluating physical and mental health across eight domains. The SF-36 was administered at baseline, post-treatment, and at the 4-week follow-up to measure quality-of-life changes linked to symptom improvement.Data Collection and AnalysisData collection comprised several tools to ensure comprehensive and accurate data acquisition. Patients’ baseline demographic and clinical characteristics were obtained through interviews and reviews of medical records. Symptom scores were recorded from the gastrointestinal symptom questionnaires, while diagnostic endoscopic jejunal aspirate and culture results were documented using the recommended collection and analysis protocols.The data was analyzed using SPSS statistical software. Descriptive statistics outlined the baseline characteristics and outcomes, with continuous variables expressed as means and standard deviations, and categorical variables as frequencies and percentages. The primary analysis involved comparing the mean changes in symptom scores and diagnostic endoscopic jejunal aspirate and culture results between the two groups using independent t-tests or Mann–Whitney U tests, depending on the normality of the data distribution. Multivariate regression analysis was conducted to control potential confounders such as age, gender, duration of diabetes, and severity of baseline symptoms, to identify significant predictors of treatment response. Variables included differences in outcome measures and the development of side effects in both treatment arms. The results of the independent tests were verified using logistic regression to determine factors that significantly contributed to the occurrence of adverse events. ANOVA was used to analyze quality-of-life data from the SF-36 and detect differences over time between the groups. Post hoc tests were conducted to determine which treatment interventions were more effective in improving quality of life [9].A systematic approach added robustness and reliability to the study, which reported the comparative efficacy and safety of rifaximin versus ciprofloxacin-metronidazole for SIBO in patients with diabetes. The findings significantly impacted clinical practice by helping shape treatment decisions and enhancing patient outcomes in this high-risk population.